© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
March 17, 2021
January 04, 2021
Bradley Corr, MD, discusses the rationale to evaluate WNT pathway inhibition in gynecologic cancers.
November 11, 2020
D. Ross Camidge, MD, PhD discusses the role of targeted therapy and how it is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer.
August 25, 2020
Erin Schenk, MD, PhD, discusses the rapidly evolving treatment landscape in lung cancer.
August 18, 2020
Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.
August 10, 2020
Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.